ANNEXA-A: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for Factor Xa (fXa) inhibitors. Circulation - Crowther, M (2014)
Abstract 2116.